MedPath

NuRx Pharmaceuticals, Inc.

🇺🇸United States
Ownership
Private
Employees
3
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2009-08-24
Last Posted Date
2009-09-03
Lead Sponsor
NuRx Pharmaceuticals, Inc.
Target Recruit Count
48
Registration Number
NCT00964132
Locations
🇺🇸

Dr. Pandit, Fountain Valley, California, United States

🇺🇸

UCSD Moores Cancer Center, La Jolla,, California, United States

🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 3 locations

Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

Phase 2
Conditions
Acute Promyelocytic Leukemia
Interventions
Drug: NRX 195183 Soft Gelatin Capsule
First Posted Date
2008-05-12
Last Posted Date
2008-05-12
Lead Sponsor
NuRx Pharmaceuticals, Inc.
Target Recruit Count
65
Registration Number
NCT00675870
Locations
🇺🇸

Sarcoma Oncology Center, Santa Monica,, California, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.